Begin main content

New at CADTH - February 2019

Last updated: February 8, 2019
Product Line: New at CADTH
Result type: Report

News and Events

Nominations are now open for our Patient and Community Advisory Committee. CADTH is looking for 12 individuals who have experience engaging with the Canadian health care system. Apply here before February 24.

Registration is now open for the 2019 CADTH Symposium, being held in Edmonton, Alberta, from April 14 to 16, 2019.

Drug Reimbursement Recommendations

CADTH recently issued the following CADTH Canadian Drug Expert Committee (CDEC) drug reimbursement recommendations:

CADTH Pan-Canadian Oncology Drug Review (pCODR)

CADTH recently issued the following pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC) Drug Reimbursement Recommendations:

  • osimertinib (Tagrisso) for the first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer whose tumours have epidermal growth factor receptor mutations
  • cabozantinib (Cabometyx) for the treatment of patients with advanced renal cell carcinoma who have received prior therapy
  • bevacizumab (Mvasi) for first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy; for treatment of patients with unresectable advanced, metastatic, or recurrent non-squamous non–small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen.

CADTH Reports

CADTH recently completed the following reports:

Rapid Response Reports — Drug

Rapid Response Reports — Medical Devices and Systems

Environmental Scans


Tell Us What You Think

We love hearing how our products and services are influencing health care policies, clinical practices, and patient outcomes. If you have a success story to share, please get in touch with your CADTH Liaison Officer.

CADTH E-Alerts: Subscribe to receive the latest CADTH news, reports, feedback opportunities, and events.